<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20220725</date><key>pmc.key</key><document><id>9295384</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1016/j.phrs.2022.106360</infon><infon key="article-id_pii">S1043-6618(22)00305-X</infon><infon key="article-id_pmc">9295384</infon><infon key="article-id_pmid">35868478</infon><infon key="article-id_publisher-id">106360</infon><infon key="elocation-id">106360</infon><infon key="kwd">Ascorbic acid COVID-19 Endothelial dysfunction L-Arginine Long-COVID Oxidative stress</infon><infon key="license">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</infon><infon key="name_0">surname:Izzo;given-names:Raffaele</infon><infon key="name_1">surname:Trimarco;given-names:Valentina</infon><infon key="name_10">surname:Messina;given-names:Nunzia</infon><infon key="name_11">surname:Mininni;given-names:Simone</infon><infon key="name_12">surname:Mussi;given-names:Chiara</infon><infon key="name_13">surname:Pelaia;given-names:Girolamo</infon><infon key="name_14">surname:Pennisi;given-names:Alfio</infon><infon key="name_15">surname:Santus;given-names:Pierachille</infon><infon key="name_16">surname:Scarpelli;given-names:Francesco</infon><infon key="name_17">surname:Tursi;given-names:Francesco</infon><infon key="name_18">surname:Zanforlin;given-names:Alessandro</infon><infon key="name_19">surname:Santulli;given-names:Gaetano</infon><infon key="name_2">surname:Mone;given-names:Pasquale</infon><infon key="name_20">surname:Trimarco;given-names:Bruno</infon><infon key="name_3">surname:Aloè;given-names:Teresita</infon><infon key="name_4">surname:Marzani;given-names:Massimo Capra</infon><infon key="name_5">surname:Diana;given-names:Antonio</infon><infon key="name_6">surname:Fazio;given-names:Giovanni</infon><infon key="name_7">surname:Mallardo;given-names:Mario</infon><infon key="name_8">surname:Maniscalco;given-names:Mauro</infon><infon key="name_9">surname:Marazzi;given-names:Giuseppe</infon><infon key="section_type">TITLE</infon><infon key="title">Keywords</infon><infon key="type">front</infon><infon key="year">2022</infon><offset>0</offset><text>Combining L-Arginine with Vitamin C Improves Long-COVID Symptoms: The Nationwide Multicenter LINCOLN Study</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>107</offset><text>Introduction</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>120</offset><text>Recent evidence suggests that oxidative stress and endothelial dysfunction play critical roles in the pathophysiology of COVID-19 and Long-COVID. We hypothesized that a supplementation combining L-Arginine (to improve endothelial function) and Vitamin C (to reduce oxidation) could have favorable effects on Long-COVID symptoms.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>449</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>457</offset><text>We designed a nationwide multicenter clinical study (LINCOLN: L-Arginine and Vitamin C improves Long-COVID), in which a survey assessing several symptoms that have been associated with Long-COVID was administered to COVID-19 survivors; effort perception was measured using the Borg scale. Patients were divided in two groups, with a 2:1 ratio: the first group included patients treated with L-Arginine + Vitamin C, whereas the second group was treated with a multivitamin combination (alternative treatment). Before administering the survey, patients completed 30 days of treatment.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1040</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1048</offset><text>1590 patients were initially enrolled, of which 1390 completed the study. Following a 30-day treatment with L-Arginine + Vitamin C, the survey revealed that patients in this treatment group had significantly lower scores compared to the other group. There were no other significant differences between the two groups. When examining effort perception, we observed a significantly lower value (p&lt;0.0001) in patients receiving L-Arginine + Vitamin C compared to the alternative-treatment arm.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1539</offset><text>Conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1551</offset><text>Taken together, our findings indicate that the supplementation with L-Arginine + Vitamin C has beneficial effects in Long-COVID, in terms of reducing its typical symptoms and improving effort perception.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1755</offset><text>Graphical abstract</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1774</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1787</offset><text>The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to a global healthcare crisis. The global pandemic has resulted also in job losses and economic hardships. Although efficacious vaccines have been recently developed, it is important to better understand SARS-CoV-2-mediated pathology, especially because many survivors are experiencing chronic symptoms of the disease, including metabolic disturbances, even months after the initial infection occurred (“Long-COVID”).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2341</offset><text>While initial studies on COVID-19 primarily focused on the pulmonary manifestations of the disease, other organs including heart, brain, kidney, and the pancreas, were shown to be affected by COVID-19. In the Spring of 2020, we were among the first groups to indicate a link between COVID-19 and endothelial dysfunction, and our view has been later confirmed by other investigators, associating the systemic manifestations of the disease to a direct or indirect involvement of the endothelium. Indeed, endothelial cells express all co-factors necessary for the internalization of SARS-CoV-2 in host cells, including angiotensin converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2), cathepsins B and D, neuropilin-1, transferrin receptor, and others, thereby representing a natural target of SARS-CoV-2. Thus, COVID-19 affects not only the epithelial cells of the lung, but also endothelial cells across the whole body, leading to a generalized endothelial damage. Endothelial cells are known to play instrumental roles in the maintenance of vascular homeostasis and in the regulation of vascular tone. Endothelial damage, caused directly by SARS-CoV-2 infection and/or by the ensuing inflammation, can shift the vascular equilibrium towards an altered vascular tone, an increased permeabilization, with subsequent tissue edema, and a pro-coagulant state, which can lead to thromboembolism; most of these findings have been substantiated by autopsies of COVID-19 patients since the outbreak of the pandemic. Further supporting our theory of a central role of the endothelium in COVID-19, patients with endothelial dysfunction (e.g. hypertension, smoking, pre-existing diabetes, obesity, and presence of cardiovascular disease) are particularly vulnerable and have adverse outcomes in COVID-19. Equally important, clinical trials testing whether interventions that ameliorate endothelial dysfunction can have beneficial effects in COVID-19 patients are ongoing and we have obtained very encouraging interim results in a randomized study testing L-Arginine oral supplementation in COVID-19 hospitalized patients.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4468</offset><text>L-Arginine is an amino acid that acts as a substrate for endothelial nitric oxide (NO) synthase (eNOS), a key enzyme in endothelial cells; it has been previously shown to significantly improve endothelial function, providing a strong rationale for its use in COVID-19 patients. Additionally, beneficial effects of L-Arginine on the regulation of immune responses have been reported. Similarly, recent clinical trials have demonstrated that Vitamin C improves the oxidative imbalance and vascular remodeling induced by different stressors and attenuates endothelial barrier permeability, an aspect that has major implications in infectious disorders (including COVID-19), which are also known to cause a systemic surge in oxidative stress. So, the antioxidant roles of Vitamin C and its protective effects on endothelial permeability could come into effect especially in post-infection recovery.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5363</offset><text>Therefore, we inferred that associating Vitamin C with other nutraceuticals playing similar actions, like L-Arginine, could be useful. On these grounds, considering that both L-Arginine and Vitamin C are known to improve endothelial function and reduce vascular permeability during infectious disorders, and based on the emerging role of vascular permeability in Long-COVID, we designed a study to assess the effects of a combination of L-Arginine and Vitamin C in Long-COVID.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>5840</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5848</offset><text>Study design and participants</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5878</offset><text>This epidemiological observational study (LINCOLN: L-Arginine and Vitamin C improves Long-COVID) starts from the medical need to understand Long-COVID disease. For this reason, in January 2022, we designed a survey based on the Nature Medicine paper published in April 2021 and to the current national recommendations on the management of Long-COVID (https://www.iss.it/documents/20126/0/Rapporto+ISS+COVID-19+n.15_2021_EN.pdf/dd962ad9-fa53-73dd-7759-55cb5c167675?t=1627575304593). Our research group includes 16 key opinion leaders belonging to different Italian Regions; a group of physicians (see appendix) participated in actually administering the survey to patients. The survey was revised by the key opinion leaders and shared with the general practitioners of the nation with the aim to enroll the highest number of patients.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6712</offset><text>The surveys included the following evaluations: patient age, sex, days from RT-qPCR negativization, hospitalization for moderate/severe COVID-19. Furthermore, the physicians needed to assess on a scale from 1 to 3 (where 1 is absence of the symptom, 2 is the presence of a mild symptom, and 3 is the presence of a severe symptom) - the following symptoms: fatigue, shortness of breath, chest tightness, dizziness, gastrointestinal disorders, headache, anosmia, difficulties in concentrating, sleep disturbances.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7224</offset><text>Finally, effort perception was evaluated using the Borg modified 0-10 Rating of perceived exertion scale, with a score from 0 to 10 (where 10 indicate no tolerance), as we previously described. We enrolled two groups of COVID-19 survivors who had been COVID-19 negative (confirmation to be SARS-CoV-2 negative via RT-qPCR test) for at least 4 weeks. The first group included patients who were treated with 2 vials/day of Bioarginina® C (L-Arginine 1.66 g in association with 500 mg of liposomal Vitamin C, Damor, Naples, Italy). The second group (alternative treatment) was treated with a multivitamin combination (Vitamin B1: 388 mg; Vitamin B2: 443 mg; Nicotinamide:18 mg; Folic Acid: 200 µg; Pantothenic acid: 2493 g; Vitamin B6: 831 mg; Vitamin B12: 416 µg). The ratio between the number of components of the first and the second group was 2:1. Before administering the survey, the patients of both groups completed 30 days of treatment. Damor had no role in the design and conduction of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8412</offset><text>Eligible patients were men and non-pregnant women who were at least 18-year-old, screened by applying the following eligibility criteria:</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8550</offset><text>Inclusion criteria</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8569</offset><text>Previous diagnosis of COVID-19 confirmed by RT-qPCR.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8622</offset><text>COVID-19 negativization confirmed by RT-qPCR from at least 4 weeks before joining the study.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8715</offset><text>Presence COVID-19 sequelae that extend beyond four weeks after initial infection</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8796</offset><text>Presence of the following conditions: </text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8835</offset><text>Exclusion criteria</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8854</offset><text>Refusal to participate;</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8878</offset><text>History of L-Arginine or Vitamin C intolerance;</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8926</offset><text>Pregnancy or breastfeeding;</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8954</offset><text>Cancer;</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8962</offset><text>Diagnosis of chronic pulmonary disease - currently under treatment;</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9030</offset><text>Use of immunosuppressive drugs, or cytotoxic chemotherapy within the previous three weeks;</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9121</offset><text>Enrollment into an investigational treatment study for COVID-19 in the 30 days before screening.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9218</offset><text>Ethical aspects</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9234</offset><text>The study was performed in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization - Good Clinical Practice guidelines. All patients provided their informed consent to participate in this study.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9485</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9506</offset><text>The characteristics of the participants are reported as the mean ± SD for approximately normally distributed continuous variables, as the median (interquartile range [IQR]: 25th percentile, 75th percentile) for severely skewed continuous variables and as numerical values (percentages) for categorical variables. Normal distribution of the data was assessed via normal probability plots and confirmed with the skewness/kurtosis test for normality. Statistical significance was determined by a p value &lt;0.05. In the statistical analysis, differences for continuous variables were evaluated using two-sample t-test for approximately normally distributed variables and Mann-Whitney U test for severely skewed variables. Chi-square or Fisher tests were used to measure associations between dichotomous and categorical variables. All analyses were performed using SPSS 26.0.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>10377</offset><text>Results</text></passage><passage><infon key="file">gr1_lrg.jpg</infon><infon key="id">fig0005</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>10385</offset><text>Flow chart of the study.</text></passage><passage><infon key="file">gr1_lrg.jpg</infon><infon key="id">fig0005</infon><infon key="section_type">FIG</infon><infon key="type">fig</infon><offset>10410</offset><text>Fig. 1</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10417</offset><text>1590 patients were initially enrolled, of which 1390 fulfilled the eligibility criteria and successfully completed the study, as shown in the flow chart in Fig. 1.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10581</offset><text>There were no significant differences in terms of age (55.3±15.8 vs 55.5±15.6; ns), male sex (49.8% vs 51.8%; ns), hospitalization (7.9% vs 9.2%; ns) between the group treated with L-Arginine + Vitamin C and the group treated with alternative treatment. Notably, no difference in the time from SARS-Cov-2 negativization was noted between arginine and alternative treated patients (33.8±24.9 vs 31.5±24.0 days; ns).</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>11000</offset><text>Survey results in the two groups of patients.</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th/&gt;&lt;th/&gt;&lt;th&gt;&lt;bold&gt;Alternative Treatment&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;L-Arginine + Vitamin C&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;p&lt;/bold&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Asthenia&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;0.4&lt;/td&gt;&lt;td&gt;94.9&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;5.2&lt;/td&gt;&lt;td&gt;4.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;94.4&lt;/td&gt;&lt;td&gt;1.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Dyspnea&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;5.4&lt;/td&gt;&lt;td&gt;74.2&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;55.1&lt;/td&gt;&lt;td&gt;25.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;39.5&lt;/td&gt;&lt;td&gt;0.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Chest tightness&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;26.3&lt;/td&gt;&lt;td&gt;86.1&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;50.9&lt;/td&gt;&lt;td&gt;13.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;22.8&lt;/td&gt;&lt;td&gt;0.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Dizziness&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;66.6&lt;/td&gt;&lt;td&gt;87.3&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;25.9&lt;/td&gt;&lt;td&gt;11.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;7.5&lt;/td&gt;&lt;td&gt;1.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Gastrointestinal disorders&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;63.3&lt;/td&gt;&lt;td&gt;87.7&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;26.7&lt;/td&gt;&lt;td&gt;11.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;10.0&lt;/td&gt;&lt;td&gt;0.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Headache&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;39.2&lt;/td&gt;&lt;td&gt;81.8&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;44.1&lt;/td&gt;&lt;td&gt;16.8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;16.7&lt;/td&gt;&lt;td&gt;1.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Anosmia&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;52.0&lt;/td&gt;&lt;td&gt;87.2&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;34.0&lt;/td&gt;&lt;td&gt;11.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;14.0&lt;/td&gt;&lt;td&gt;1.8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Concentration difficulty&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;32.8&lt;/td&gt;&lt;td&gt;79.1&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;46.8&lt;/td&gt;&lt;td&gt;19.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;20.4&lt;/td&gt;&lt;td&gt;1.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Sleeplessness&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;39.5&lt;/td&gt;&lt;td&gt;80.7&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;42.6&lt;/td&gt;&lt;td&gt;17.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;17.9&lt;/td&gt;&lt;td&gt;1.8&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>11046</offset><text>Table 1	 	</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th/&gt;&lt;th/&gt;&lt;th&gt;&lt;bold&gt;Alternative Treatment&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;L-Arginine + Vitamin C&lt;/bold&gt;&lt;/th&gt;&lt;th&gt;&lt;bold&gt;p&lt;/bold&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Asthenia&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;0.4&lt;/td&gt;&lt;td&gt;94.9&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;5.2&lt;/td&gt;&lt;td&gt;4.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;94.4&lt;/td&gt;&lt;td&gt;1.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Dyspnea&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;5.4&lt;/td&gt;&lt;td&gt;74.2&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;55.1&lt;/td&gt;&lt;td&gt;25.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;39.5&lt;/td&gt;&lt;td&gt;0.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Chest tightness&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;26.3&lt;/td&gt;&lt;td&gt;86.1&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;50.9&lt;/td&gt;&lt;td&gt;13.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;22.8&lt;/td&gt;&lt;td&gt;0.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Dizziness&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;66.6&lt;/td&gt;&lt;td&gt;87.3&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;25.9&lt;/td&gt;&lt;td&gt;11.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;7.5&lt;/td&gt;&lt;td&gt;1.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Gastrointestinal disorders&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;63.3&lt;/td&gt;&lt;td&gt;87.7&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;26.7&lt;/td&gt;&lt;td&gt;11.7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;10.0&lt;/td&gt;&lt;td&gt;0.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Headache&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;39.2&lt;/td&gt;&lt;td&gt;81.8&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;44.1&lt;/td&gt;&lt;td&gt;16.8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;16.7&lt;/td&gt;&lt;td&gt;1.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Anosmia&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;52.0&lt;/td&gt;&lt;td&gt;87.2&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;34.0&lt;/td&gt;&lt;td&gt;11.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;14.0&lt;/td&gt;&lt;td&gt;1.8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Concentration difficulty&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;32.8&lt;/td&gt;&lt;td&gt;79.1&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;46.8&lt;/td&gt;&lt;td&gt;19.4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;20.4&lt;/td&gt;&lt;td&gt;1.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;&lt;bold&gt;Sleeplessness&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;&lt;bold&gt;Absent (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;39.5&lt;/td&gt;&lt;td&gt;80.7&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Mild (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;42.6&lt;/td&gt;&lt;td&gt;17.5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;bold&gt;Severe (%)&lt;/bold&gt;&lt;/td&gt;&lt;td&gt;17.9&lt;/td&gt;&lt;td&gt;1.8&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>11057</offset><text>		Alternative Treatment	L-Arginine + Vitamin C	p	 	Asthenia	Absent (%)	0.4	94.9	&lt;0.0001	 	Mild (%)	5.2	4.0	 	Severe (%)	94.4	1.1	 	Dyspnea	Absent (%)	5.4	74.2	&lt;0.0001	 	Mild (%)	55.1	25.4	 	Severe (%)	39.5	0.4	 	Chest tightness	Absent (%)	26.3	86.1	&lt;0.0001	 	Mild (%)	50.9	13.4	 	Severe (%)	22.8	0.5	 	Dizziness	Absent (%)	66.6	87.3	&lt;0.0001	 	Mild (%)	25.9	11.6	 	Severe (%)	7.5	1.1	 	Gastrointestinal disorders	Absent (%)	63.3	87.7	&lt;0.0001	 	Mild (%)	26.7	11.7	 	Severe (%)	10.0	0.6	 	Headache	Absent (%)	39.2	81.8	&lt;0.0001	 	Mild (%)	44.1	16.8	 	Severe (%)	16.7	1.4	 	Anosmia	Absent (%)	52.0	87.2	&lt;0.0001	 	Mild (%)	34.0	11.0	 	Severe (%)	14.0	1.8	 	Concentration difficulty	Absent (%)	32.8	79.1	&lt;0.0001	 	Mild (%)	46.8	19.4	 	Severe (%)	20.4	1.5	 	Sleeplessness	Absent (%)	39.5	80.7	&lt;0.0001	 	Mild (%)	42.6	17.5	 	Severe (%)	17.9	1.8	 	</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11896</offset><text>Following a 30-day treatment with L-Arginine + Vitamin C, the survey revealed that patients in this treatment group had significantly lower scores (which means less severe long-COVID symptoms) compared to the other group (L-Arginine + Vitamin C: 8.15±1.3 vs Alternative treatment: 13.9±2.3, p&lt;0.001); remarkably, the treatment with L-Arginine + Vitamin C had favorable effects on all the symptoms included in the survey ( Table 1).</text></passage><passage><infon key="file">gr2_lrg.jpg</infon><infon key="id">fig0010</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>12330</offset><text>. Borg score assessed after 1 month in the groups of patients receiving L-Arginine + Vitamin C or alternative treatment. Box plots indicate upper/lower quartiles, the line in the middle of each box is the mean, and the whiskers represent the min–max of values; *:P&lt;0.0001.</text></passage><passage><infon key="file">gr2_lrg.jpg</infon><infon key="id">fig0010</infon><infon key="section_type">FIG</infon><infon key="type">fig</infon><offset>12605</offset><text>Fig. 2</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12612</offset><text>When examining the effort perception (modified Borg scale), we observed a significantly lower value (p&lt;0.0001; Fig. 2) in patients receiving L-Arginine + Vitamin C, compared to the alternative-treatment arm, indicating that L-Arginine + Vitamin C led to a better effort perception.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>12894</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>12905</offset><text>This study is the first to show the beneficial effects of the combination of L-Arginine and Vitamin C in Long-COVID. Our investigation was based on a robust rationale, i.e. targeting endothelial dysfunction in Long-COVID. Indeed, endothelial cell infection with consecutive inflammatory cell recruitment and endothelial dysfunction could explain the impaired microcirculation observed across vascular beds in COVID-19, triggering vasoconstriction, ischemia, and a pro-coagulant state. Consistent with our view, several investigators had proposed that endotheliitis could be a critical mechanism underlying systemic impaired microcirculatory function observed in different vascular beds in patients experiencing Long-COVID symtoms.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>13636</offset><text>Of note, a recent clinical study has demonstrated that COVID-19 patients develop endothelial dysfunction, which remains significantly impaired compared to healthy controls subjects at a 6-month follow-up, implicating that endothelial dysfunction is a main player in both acute COVID-19 and Long-COVID. Interestingly, increased numbers of circulating endothelial cells, a biomarker of vascular injury, most likely detached from the vessel wall due to pathological insults, were found to significantly correlate with the severity of COVID-19 outcome. Strikingly, elevated levels of circulating endothelial cells persisted in recovered COVID-19 convalescent patients, denoting long-term detrimental effects of SARS-CoV-2 infection on endothelial function. Actual signs of endothelial damage (denoted by glycocalyx damage) have been reported in convalescent COVID-19 patients after mild disease progression without hospitalization. Other studies evidenced that sustained endotheliopathy is common in convalescent COVID-19 subjects, and that Long-COVID symptoms, specifically non-respiratory symptoms, are mainly due to persistent endothelial dysfunction.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>14787</offset><text>Our data are fully in agreement with previous reports implying that after the acute phase of COVID-19, the disease is dominated by immunopathological pro-inflammatory elements. In fact, previous investigations have actually demonstrated that reduced levels of L-Arginine increase the generation of reactive oxygen species (ROS), aggravating inflammation. Besides, in vitro assays revealed that the T cell proliferative capacity is significantly reduced among COVID-19 patients and can be restored through L-Arginine supplementation. COVID-19 patients with severe symptoms present an increased level of myeloid-derived suppressor cells, directly correlated to an enhanced activity of arginase – the enzyme responsible for metabolizing L-Arginine to ornithine and urea. Another recent investigation has demonstrated an inverse correlation between L-Arginine level and platelet activation, a major contributor to thromboembolic complications of COVID-19. While eNOS produces physiological levels of NO, the inducible NO synthase (iNOS) is mainly expressed under inflammatory stimuli in parenchymal cells and leucocytes, producing much larger amounts of NO, and its exact role in COVID-19 remains to be fully clarified.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16005</offset><text>As a critical driver of inflammation and oxidative stress, endothelial dysfunction has also been involved in the pathophysiology of the neurological symptoms of COVID-19 and Long-COVID. Fatigue is a prevailing symptom in Long-COVID patients, and previous trials have evidenced a significant decrease in fatigue in subjects treated with Vitamin C, fully consistent with our present results. Supporting our strategy to combine L-Arginine to Vitamin C, previous investigations have shown that ascorbic acid can synergistically improve the effects of other agents: for example, if added to glucagon-like peptide 1 (GLP-1) agonists, it reduces ROS generation in diabetic patients, in combination with metformin, it reduces macro- and microvascular diabetic complications.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>16772</offset><text>Strengths and limitations</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16798</offset><text>Strengths of the study include its multicenter nature and the large population enrolled. Nevertheless, we do reckon that our research is not exempt from limitations. For instance, we did not assess the blood levels of nitrates and nitrite, vitamin C, or citrulline in our patients; moreover, we did not administer the survey at baseline but only after 30 days. Hence, one may argue that the patients who received L-Arginine + Vitamin C were somehow healthier than the other group before starting the treatment. However, this hypothesis seems unlikely since patients were enrolled in the study by their family physicians who had prescribed different treatments in patients with similar clinical characteristics only on account of little guidance on managing Long-COVID.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>17567</offset><text>CRediT authorship contribution statement</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>17608</offset><text>Raffaele Izzo, Valentina Trimarco, Bruno Trimarco: Conceptualization, Methodology, Data, curation. Pasquale Mone: Visualization, Writing- Reviewing and Editing. Teresita Aloè, Massimo, Capra Marzani, Antonio Diana, Giovanni Fazio, Mario Mallardo, Mauro Maniscalco,Giuseppe Marazzi, Nunzia Messina, Simone Mininni, Chiara Mussi, Girolamo Pelaia, Alfio Pennisi, Pierachille Santus, Francesco Scarpelli, Francesco Tursi, Alessandro Zanforlin: Investigation. Gaetano Santulli: Writing- Original draft preparation, Supervision.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>18132</offset><text>Declarations of interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>18157</offset><text>none.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>18163</offset><text>References</text></passage><passage><infon key="name_0">surname:Page;given-names:J.H.</infon><infon key="pub-id_doi">10.1136/bmjopen-2021-055137</infon><infon key="section_type">REF</infon><infon key="source">BMJ Open</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2022</infon><offset>18174</offset><text>Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study</text></passage><passage><infon key="name_0">surname:Gachter;given-names:M.</infon><infon key="name_1">surname:Huber;given-names:F.</infon><infon key="name_2">surname:Meier;given-names:M.</infon><infon key="pub-id_doi">10.1016/j.frl.2021.102638</infon><infon key="section_type">REF</infon><infon key="source">Financ Res Lett</infon><infon key="type">ref</infon><infon key="volume">102638</infon><infon key="year">2022</infon><offset>18303</offset><text>A shot for the US economy</text></passage><passage><infon key="fpage">119</infon><infon key="lpage">126</infon><infon key="name_0">surname:Boggiano;given-names:C.</infon><infon key="pub-id_doi">10.7326/M21-3669</infon><infon key="pub-id_pmid">34724404</infon><infon key="section_type">REF</infon><infon key="source">Ann Intern Med</infon><infon key="type">ref</infon><infon key="volume">175</infon><infon key="year">2022</infon><offset>18329</offset><text>Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19</text></passage><passage><infon key="fpage">297</infon><infon key="lpage">299</infon><infon key="name_0">surname:Morens;given-names:D.M.</infon><infon key="name_1">surname:Taubenberger;given-names:J.K.</infon><infon key="name_2">surname:Fauci;given-names:A.S.</infon><infon key="pub-id_doi">10.1056/NEJMp2118468</infon><infon key="pub-id_pmid">34910863</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">386</infon><infon key="year">2022</infon><offset>18477</offset><text>Universal Coronavirus Vaccines - An Urgent Need</text></passage><passage><infon key="name_0">surname:Sievers;given-names:B.L.</infon><infon key="pub-id_doi">10.1126/scitranslmed.abn7842</infon><infon key="section_type">REF</infon><infon key="source">Sci Transl Med, eabn7842</infon><infon key="type">ref</infon><infon key="year">2022</infon><offset>18525</offset><text>Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses</text></passage><passage><infon key="fpage">109</infon><infon key="name_0">surname:Fauci;given-names:A.S.</infon><infon key="pub-id_doi">10.1126/science.abi8397</infon><infon key="pub-id_pmid">33833099</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">372</infon><infon key="year">2021</infon><offset>18660</offset><text>The story behind COVID-19 vaccines</text></passage><passage><infon key="fpage">C1</infon><infon key="lpage">C11</infon><infon key="name_0">surname:Desai;given-names:A.D.</infon><infon key="name_1">surname:Lavelle;given-names:M.</infon><infon key="name_2">surname:Boursiquot;given-names:B.C.</infon><infon key="name_3">surname:Wan;given-names:E.Y.</infon><infon key="pub-id_doi">10.1152/ajpcell.00375.2021</infon><infon key="pub-id_pmid">34817268</infon><infon key="section_type">REF</infon><infon key="source">Am J Physiol Cell Physiol</infon><infon key="type">ref</infon><infon key="volume">322</infon><infon key="year">2022</infon><offset>18695</offset><text>Long-term complications of COVID-19</text></passage><passage><infon key="name_0">surname:Del Rio;given-names:C.</infon><infon key="name_1">surname:Collins;given-names:L.F.</infon><infon key="name_2">surname:Malani;given-names:P.</infon><infon key="pub-id_doi">10.1001/jama.2020.19719</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>18731</offset><text>Long-term Health Consequences of COVID-19</text></passage><passage><infon key="fpage">5</infon><infon key="lpage">6</infon><infon key="name_0">surname:Gaffney;given-names:A.W.</infon><infon key="pub-id_doi">10.1016/j.amjmed.2021.07.037</infon><infon key="pub-id_pmid">34428463</infon><infon key="section_type">REF</infon><infon key="source">Am J Med</infon><infon key="type">ref</infon><infon key="volume">135</infon><infon key="year">2022</infon><offset>18773</offset><text>The Long COVID Conundrum</text></passage><passage><infon key="name_0">surname:Raveendran;given-names:A.V.</infon><infon key="name_1">surname:Misra;given-names:A.</infon><infon key="pub-id_doi">10.1016/j.dsx.2021.102235</infon><infon key="section_type">REF</infon><infon key="source">Diabetes Metab Syndr</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2021</infon><offset>18798</offset><text>Post COVID-19 Syndrome (&quot;Long COVID&quot;) and Diabetes: Challenges in Diagnosis and Management</text></passage><passage><infon key="fpage">o143</infon><infon key="name_0">surname:Zimmermann;given-names:P.</infon><infon key="name_1">surname:Pittet;given-names:L.F.</infon><infon key="name_2">surname:Curtis;given-names:N.</infon><infon key="pub-id_doi">10.1136/bmj.o143</infon><infon key="pub-id_pmid">35058281</infon><infon key="section_type">REF</infon><infon key="source">BMJ</infon><infon key="type">ref</infon><infon key="volume">376</infon><infon key="year">2022</infon><offset>18889</offset><text>Long covid in children and adolescents</text></passage><passage><infon key="fpage">601</infon><infon key="lpage">615</infon><infon key="name_0">surname:Nalbandian;given-names:A.</infon><infon key="pub-id_doi">10.1038/s41591-021-01283-z</infon><infon key="pub-id_pmid">33753937</infon><infon key="section_type">REF</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2021</infon><offset>18928</offset><text>Post-acute COVID-19 syndrome</text></passage><passage><infon key="fpage">2031</infon><infon key="lpage">2032</infon><infon key="name_0">surname:Siegelman;given-names:J.N.</infon><infon key="pub-id_doi">10.1001/jama.2020.22130</infon><infon key="pub-id_pmid">33175108</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">324</infon><infon key="year">2020</infon><offset>18957</offset><text>Reflections of a COVID-19 Long Hauler</text></passage><passage><infon key="fpage">2549</infon><infon key="lpage">2565</infon><infon key="name_0">surname:Feldman;given-names:E.L.</infon><infon key="pub-id_doi">10.2337/dbi20-0032</infon><infon key="pub-id_pmid">32938731</infon><infon key="section_type">REF</infon><infon key="source">Diabetes</infon><infon key="type">ref</infon><infon key="volume">69</infon><infon key="year">2020</infon><offset>18995</offset><text>COVID-19 and Diabetes: A Collision and Collusion of Two Diseases</text></passage><passage><infon key="fpage">869</infon><infon key="lpage">875</infon><infon key="name_0">surname:Raveendran;given-names:A.V.</infon><infon key="name_1">surname:Jayadevan;given-names:R.</infon><infon key="name_2">surname:Sashidharan;given-names:S.</infon><infon key="pub-id_doi">10.1016/j.dsx.2021.04.007</infon><infon key="pub-id_pmid">33892403</infon><infon key="section_type">REF</infon><infon key="source">Diabetes Metab Syndr</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2021</infon><offset>19060</offset><text>Long COVID: An overview</text></passage><passage><infon key="name_0">surname:Stokes;given-names:A.C.</infon><infon key="pub-id_doi">10.1371/journal.pmed.1003571</infon><infon key="section_type">REF</infon><infon key="source">PLoS Med</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2021</infon><offset>19084</offset><text>COVID-19 and excess mortality in the United States: A county-level analysis</text></passage><passage><infon key="fpage">693</infon><infon key="lpage">694</infon><infon key="name_0">surname:Sathish;given-names:T.</infon><infon key="name_1">surname:Anton;given-names:M.C.</infon><infon key="name_2">surname:Sivakumar;given-names:T.</infon><infon key="pub-id_doi">10.1111/1753-0407.13187</infon><infon key="pub-id_pmid">33893710</infon><infon key="section_type">REF</infon><infon key="source">J Diabetes</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2021</infon><offset>19160</offset><text>New-onset diabetes in &quot;long COVID&quot;</text></passage><passage><infon key="name_0">surname:Montefusco;given-names:L.</infon><infon key="pub-id_doi">10.1038/s42255-021-00407-6</infon><infon key="section_type">REF</infon><infon key="source">Nat Metab</infon><infon key="type">ref</infon><infon key="year">2021</infon><offset>19195</offset><text>Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection</text></passage><passage><infon key="fpage">1268</infon><infon key="lpage">1269</infon><infon key="name_0">surname:Fauci;given-names:A.S.</infon><infon key="name_1">surname:Lane;given-names:H.C.</infon><infon key="name_2">surname:Redfield;given-names:R.R.</infon><infon key="pub-id_doi">10.1056/NEJMe2002387</infon><infon key="pub-id_pmid">32109011</infon><infon key="section_type">REF</infon><infon key="source">The New England journal of medicine</infon><infon key="type">ref</infon><infon key="volume">382</infon><infon key="year">2020</infon><offset>19279</offset><text>Covid-19 - Navigating the Uncharted</text></passage><passage><infon key="fpage">493</infon><infon key="lpage">497</infon><infon key="name_0">surname:Paules;given-names:C.I.</infon><infon key="name_1">surname:Fauci;given-names:A.S.</infon><infon key="pub-id_doi">10.1016/j.medj.2021.04.015</infon><infon key="pub-id_pmid">33899041</infon><infon key="section_type">REF</infon><infon key="source">Med (N Y)</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2021</infon><offset>19315</offset><text>COVID-19: The therapeutic landscape</text></passage><passage><infon key="fpage">1278</infon><infon key="lpage">1280</infon><infon key="name_0">surname:Hoehl;given-names:S.</infon><infon key="pub-id_doi">10.1056/NEJMc2001899</infon><infon key="pub-id_pmid">32069388</infon><infon key="section_type">REF</infon><infon key="source">The New England journal of medicine</infon><infon key="type">ref</infon><infon key="volume">382</infon><infon key="year">2020</infon><offset>19351</offset><text>Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China</text></passage><passage><infon key="fpage">1177</infon><infon key="lpage">1179</infon><infon key="name_0">surname:Zou;given-names:L.</infon><infon key="pub-id_doi">10.1056/NEJMc2001737</infon><infon key="pub-id_pmid">32074444</infon><infon key="section_type">REF</infon><infon key="source">The New England journal of medicine</infon><infon key="type">ref</infon><infon key="volume">382</infon><infon key="year">2020</infon><offset>19425</offset><text>SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients</text></passage><passage><infon key="fpage">37</infon><infon key="lpage">40</infon><infon key="name_0">surname:Sheahan;given-names:T.P.</infon><infon key="name_1">surname:Frieman;given-names:M.B.</infon><infon key="pub-id_doi">10.1016/j.coviro.2020.05.010</infon><infon key="pub-id_pmid">32569751</infon><infon key="section_type">REF</infon><infon key="source">Curr Opin Virol</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">2020</infon><offset>19499</offset><text>The continued epidemic threat of SARS-CoV-2 and implications for the future of global public health</text></passage><passage><infon key="fpage">141</infon><infon key="lpage">154</infon><infon key="name_0">surname:Hu;given-names:B.</infon><infon key="name_1">surname:Guo;given-names:H.</infon><infon key="name_2">surname:Zhou;given-names:P.</infon><infon key="name_3">surname:Shi;given-names:Z.L.</infon><infon key="pub-id_doi">10.1038/s41579-020-00459-7</infon><infon key="pub-id_pmid">33024307</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Microbiol</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2021</infon><offset>19599</offset><text>Characteristics of SARS-CoV-2 and COVID-19</text></passage><passage><infon key="fpage">123</infon><infon key="lpage">125</infon><infon key="name_0">surname:Accili;given-names:D.</infon><infon key="pub-id_doi">10.1038/s42255-020-00339-7</infon><infon key="pub-id_pmid">33432203</infon><infon key="section_type">REF</infon><infon key="source">Nat Metab</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2021</infon><offset>19642</offset><text>Can COVID-19 cause diabetes</text></passage><passage><infon key="name_0">surname:Denson;given-names:J.L.</infon><infon key="pub-id_doi">10.1001/jamanetworkopen.2021.40568</infon><infon key="section_type">REF</infon><infon key="source">JAMA Netw Open</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2021</infon><offset>19670</offset><text>Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19</text></passage><passage><infon key="fpage">1017</infon><infon key="lpage">1032</infon><infon key="name_0">surname:Gupta;given-names:A.</infon><infon key="pub-id_doi">10.1038/s41591-020-0968-3</infon><infon key="pub-id_pmid">32651579</infon><infon key="section_type">REF</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2020</infon><offset>19768</offset><text>Extrapulmonary manifestations of COVID-19</text></passage><passage><infon key="fpage">1417</infon><infon key="name_0">surname:Sardu;given-names:C.</infon><infon key="pub-id_doi">10.3390/jcm9051417</infon><infon key="section_type">REF</infon><infon key="source">J Clin Med</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2020</infon><offset>19810</offset><text>Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence</text></passage><passage><infon key="name_0">surname:Santulli;given-names:G.</infon><infon key="name_1">surname:Morelli;given-names:M.</infon><infon key="name_2">surname:Gambardella;given-names:J.</infon><infon key="section_type">REF</infon><infon key="source">BMJ</infon><infon key="type">ref</infon><infon key="volume">368</infon><infon key="year">2020</infon><offset>19960</offset><text>Is Endothelial Dysfunction the Concealed Cornerstone of COVID-19?</text></passage><passage><infon key="fpage">8076</infon><infon key="lpage">8091</infon><infon key="name_0">surname:Qin;given-names:Z.</infon><infon key="pub-id_doi">10.7150/thno.61810</infon><infon key="pub-id_pmid">34335981</infon><infon key="section_type">REF</infon><infon key="source">Theranostics</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2021</infon><offset>20026</offset><text>Endothelial cell infection and dysfunction, immune activation in severe COVID-19</text></passage><passage><infon key="fpage">3038</infon><infon key="lpage">3044</infon><infon key="name_0">surname:Libby;given-names:P.</infon><infon key="name_1">surname:Luscher;given-names:T.</infon><infon key="pub-id_doi">10.1093/eurheartj/ehaa623</infon><infon key="pub-id_pmid">32882706</infon><infon key="section_type">REF</infon><infon key="source">Eur Heart J</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2020</infon><offset>20107</offset><text>COVID-19 is, in the end, an endothelial disease</text></passage><passage><infon key="name_0">surname:Gu;given-names:S.X.</infon><infon key="pub-id_doi">10.1038/s41569-020-00469-1</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Cardiol</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>20155</offset><text>Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation</text></passage><passage><infon key="name_0">surname:Perea Polak;given-names:A.</infon><infon key="pub-id_doi">10.1111/ijd.15267</infon><infon key="section_type">REF</infon><infon key="source">Int J Dermatol</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>20246</offset><text>Complement-mediated thrombogenic vasculopathy in COVID-19</text></passage><passage><infon key="fpage">389</infon><infon key="lpage">391</infon><infon key="name_0">surname:Teuwen;given-names:L.A.</infon><infon key="name_1">surname:Geldhof;given-names:V.</infon><infon key="name_2">surname:Pasut;given-names:A.</infon><infon key="name_3">surname:Carmeliet;given-names:P.</infon><infon key="pub-id_doi">10.1038/s41577-020-0343-0</infon><infon key="pub-id_pmid">32439870</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Immunol</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2020</infon><offset>20304</offset><text>COVID-19: the vasculature unleashed</text></passage><passage><infon key="fpage">381</infon><infon key="name_0">surname:Mesquida;given-names:J.</infon><infon key="pub-id_doi">10.1186/s13054-021-03803-2</infon><infon key="pub-id_pmid">34749792</infon><infon key="section_type">REF</infon><infon key="source">Crit Care</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2021</infon><offset>20340</offset><text>Peripheral microcirculatory alterations are associated with the severity of acute respiratory distress syndrome in COVID-19 patients admitted to intermediate respiratory and intensive care units</text></passage><passage><infon key="name_0">surname:Schmaier;given-names:A.A.</infon><infon key="pub-id_doi">10.1172/jci.insight.151527</infon><infon key="section_type">REF</infon><infon key="source">JCI Insight</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2021</infon><offset>20535</offset><text>Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19</text></passage><passage><infon key="name_0">surname:Otifi;given-names:H.M.</infon><infon key="name_1">surname:Adiga;given-names:B.K.</infon><infon key="pub-id_doi">10.1016/j.amjms.2021.12.010</infon><infon key="section_type">REF</infon><infon key="source">Am J Med Sci</infon><infon key="type">ref</infon><infon key="year">2022</infon><offset>20618</offset><text>Endothelial Dysfunction in Covid-19</text></passage><passage><infon key="name_0">surname:Kelliher;given-names:S.</infon><infon key="pub-id_doi">10.1111/jth.15660</infon><infon key="section_type">REF</infon><infon key="source">J Thromb Haemost</infon><infon key="type">ref</infon><infon key="year">2022</infon><offset>20654</offset><text>Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis</text></passage><passage><infon key="name_0">surname:Amraei;given-names:R.</infon><infon key="pub-id_doi">10.1073/pnas.2113874119</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci U S A</infon><infon key="type">ref</infon><infon key="volume">119</infon><infon key="year">2022</infon><offset>20778</offset><text>Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>20888</offset><text>Gambardella, J. &amp; Santulli, G. What is linking COVID-19 and endothelial dysfunction? Updates on nanomedicine and bioengineering from the 2020 AHA Scientific Sessions. European Heart Journal (Cardiovascular Pharmacotherapy), In press (2020).</text></passage><passage><infon key="fpage">989</infon><infon key="name_0">surname:Kaur;given-names:S.</infon><infon key="name_1">surname:Tripathi;given-names:D.M.</infon><infon key="name_2">surname:Yadav;given-names:A.</infon><infon key="pub-id_doi">10.3389/fphys.2020.00989</infon><infon key="pub-id_pmid">32848893</infon><infon key="section_type">REF</infon><infon key="source">Front Physiol</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2020</infon><offset>21129</offset><text>The Enigma of Endothelium in COVID-19</text></passage><passage><infon key="name_0">surname:Matarese;given-names:A.</infon><infon key="name_1">surname:Gambardella;given-names:J.</infon><infon key="name_2">surname:Sardu;given-names:C.</infon><infon key="name_3">surname:Santulli;given-names:G.</infon><infon key="pub-id_doi">10.3390/biomedicines8110462</infon><infon key="section_type">REF</infon><infon key="source">Biomedicines</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2020</infon><offset>21167</offset><text>miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19</text></passage><passage><infon key="fpage">1111</infon><infon key="lpage">1123</infon><infon key="name_0">surname:Ahmetaj-Shala;given-names:B.</infon><infon key="pub-id_doi">10.1016/j.jacbts.2020.09.010</infon><infon key="pub-id_pmid">33073064</infon><infon key="section_type">REF</infon><infon key="source">JACC Basic Transl Sci</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2020</infon><offset>21261</offset><text>Cardiorenal Tissues Express SARS-CoV-2 Entry Genes and Basigin (BSG/CD147) Increases With Age in Endothelial Cells</text></passage><passage><infon key="name_0">surname:Mone;given-names:P.</infon><infon key="pub-id_doi">10.3390/ncrna7010009</infon><infon key="section_type">REF</infon><infon key="source">Noncoding RNA</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2021</infon><offset>21376</offset><text>miR-24 Targets the Transmembrane Glycoprotein Neuropilin-1 in Human Brain Microvascular Endothelial Cells</text></passage><passage><infon key="name_0">surname:Roberts;given-names:K.A.</infon><infon key="name_1">surname:Colley;given-names:L.</infon><infon key="name_2">surname:Agbaedeng;given-names:T.A.</infon><infon key="name_3">surname:Ellison-Hughes;given-names:G.M.</infon><infon key="name_4">surname:Ross;given-names:M.D.</infon><infon key="pub-id_doi">10.3389/fcvm.2020.598400</infon><infon key="section_type">REF</infon><infon key="source">Front Cardiovasc Med</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2020</infon><offset>21482</offset><text>Vascular Manifestations of COVID-19 - Thromboembolism and Microvascular Dysfunction</text></passage><passage><infon key="name_0">surname:Ortiz;given-names:M.E.</infon><infon key="pub-id_doi">10.1016/j.ebiom.2020.102976</infon><infon key="section_type">REF</infon><infon key="source">EBioMedicine</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">2020</infon><offset>21566</offset><text>Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract</text></passage><passage><infon key="fpage">2214</infon><infon key="lpage">2227</infon><infon key="name_0">surname:Kelesidis;given-names:T.</infon><infon key="pub-id_doi">10.1080/21505594.2021.1964329</infon><infon key="pub-id_pmid">34494942</infon><infon key="section_type">REF</infon><infon key="source">Virulence</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2021</infon><offset>21662</offset><text>The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells</text></passage><passage><infon key="name_0">surname:Varzideh;given-names:F.</infon><infon key="pub-id_doi">10.1172/JCI156624</infon><infon key="section_type">REF</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="volume">132</infon><infon key="year">2022</infon><offset>21815</offset><text>Sortilin drives hypertension by modulating sphingolipid/ceramide homeostasis and by triggering oxidative stress</text></passage><passage><infon key="fpage">1625</infon><infon key="lpage">1636</infon><infon key="name_0">surname:Gambardella;given-names:J.</infon><infon key="pub-id_doi">10.1161/HYPERTENSIONAHA.120.15130</infon><infon key="pub-id_pmid">32895019</infon><infon key="section_type">REF</infon><infon key="source">Hypertension</infon><infon key="type">ref</infon><infon key="volume">76</infon><infon key="year">2020</infon><offset>21927</offset><text>Role of Endothelial G Protein-Coupled Receptor Kinase 2 in Angioedema</text></passage><passage><infon key="fpage">477</infon><infon key="lpage">494</infon><infon key="name_0">surname:Pi;given-names:X.</infon><infon key="name_1">surname:Xie;given-names:L.</infon><infon key="name_2">surname:Patterson;given-names:C.</infon><infon key="pub-id_doi">10.1161/CIRCRESAHA.118.313237</infon><infon key="pub-id_pmid">30355249</infon><infon key="section_type">REF</infon><infon key="source">Circ Res</infon><infon key="type">ref</infon><infon key="volume">123</infon><infon key="year">2018</infon><offset>21997</offset><text>Emerging Roles of Vascular Endothelium in Metabolic Homeostasis</text></passage><passage><infon key="fpage">114</infon><infon key="lpage">128</infon><infon key="name_0">surname:Zhang;given-names:L.</infon><infon key="pub-id_doi">10.1161/CIRCULATIONAHA.120.046702</infon><infon key="pub-id_pmid">32421381</infon><infon key="section_type">REF</infon><infon key="source">Circulation</infon><infon key="type">ref</infon><infon key="volume">142</infon><infon key="year">2020</infon><offset>22061</offset><text>Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome</text></passage><passage><infon key="fpage">2404</infon><infon key="lpage">2407</infon><infon key="name_0">surname:Nagashima;given-names:S.</infon><infon key="pub-id_doi">10.1161/ATVBAHA.120.314860</infon><infon key="pub-id_pmid">32762443</infon><infon key="section_type">REF</infon><infon key="source">Arterioscler Thromb Vasc Biol</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">2020</infon><offset>22176</offset><text>Endothelial Dysfunction and Thrombosis in Patients With COVID-19-Brief Report</text></passage><passage><infon key="name_0">surname:Burkhard-Koren;given-names:N.M.</infon><infon key="pub-id_doi">10.1002/cjp2.189</infon><infon key="section_type">REF</infon><infon key="source">J Pathol Clin Res</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>22254</offset><text>Higher prevalence of pulmonary macrothrombi in SARS-CoV-2 than in influenza A: autopsy results from 'Spanish flu' 1918/1919 in Switzerland to Coronavirus disease 2019</text></passage><passage><infon key="name_0">surname:Izcovich;given-names:A.</infon><infon key="pub-id_doi">10.1371/journal.pone.0241955</infon><infon key="section_type">REF</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2020</infon><offset>22421</offset><text>Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review</text></passage><passage><infon key="name_0">surname:Fiorentino;given-names:G.</infon><infon key="pub-id_doi">10.1016/j.eclinm.2021.101125</infon><infon key="section_type">REF</infon><infon key="source">EClinicalMedicine</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">2021</infon><offset>22523</offset><text>Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis</text></passage><passage><infon key="fpage">746</infon><infon key="name_0">surname:Johansson;given-names:P.I.</infon><infon key="pub-id_doi">10.1186/s13063-020-04696-2</infon><infon key="pub-id_pmid">32847626</infon><infon key="section_type">REF</infon><infon key="source">Trials</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2020</infon><offset>22714</offset><text>The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial</text></passage><passage><infon key="name_0">surname:Liu;given-names:F.</infon><infon key="name_1">surname:Zhu;given-names:Y.</infon><infon key="name_2">surname:Zhang;given-names:J.</infon><infon key="name_3">surname:Li;given-names:Y.</infon><infon key="name_4">surname:Peng;given-names:Z.</infon><infon key="pub-id_doi">10.1136/bmjopen-2020-039519</infon><infon key="section_type">REF</infon><infon key="source">BMJ Open</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2020</infon><offset>22945</offset><text>Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial</text></passage><passage><infon key="name_0">surname:Adebayo;given-names:A.</infon><infon key="pub-id_doi">10.3390/nu13113951</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2021</infon><offset>23076</offset><text>l-Arginine and COVID-19: An Update</text></passage><passage><infon key="fpage">935</infon><infon key="lpage">945</infon><infon key="name_0">surname:Leucker;given-names:T.M.</infon><infon key="pub-id_doi">10.1016/j.jacbts.2021.09.013</infon><infon key="pub-id_pmid">34904132</infon><infon key="section_type">REF</infon><infon key="source">JACC Basic Transl Sci</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2021</infon><offset>23111</offset><text>Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial</text></passage><passage><infon key="fpage">69</infon><infon key="lpage">82</infon><infon key="name_0">surname:Ma;given-names:Z.</infon><infon key="name_1">surname:Yang;given-names:K.Y.</infon><infon key="name_2">surname:Huang;given-names:Y.</infon><infon key="name_3">surname:Lui;given-names:K.O.</infon><infon key="pub-id_doi">10.1016/j.yjmcc.2021.11.010</infon><infon key="pub-id_pmid">34838588</infon><infon key="section_type">REF</infon><infon key="source">J Mol Cell Cardiol</infon><infon key="type">ref</infon><infon key="volume">164</infon><infon key="year">2021</infon><offset>23212</offset><text>Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications</text></passage><passage><infon key="fpage">451</infon><infon key="name_0">surname:Sharma;given-names:A.</infon><infon key="pub-id_doi">10.1186/s13063-021-05361-y</infon><infon key="pub-id_pmid">34266452</infon><infon key="section_type">REF</infon><infon key="source">Trials</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2021</infon><offset>23303</offset><text>A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial</text></passage><passage><infon key="fpage">589</infon><infon key="lpage">594</infon><infon key="name_0">surname:Srivastava;given-names:S.</infon><infon key="name_1">surname:Garg;given-names:I.</infon><infon key="name_2">surname:Hembrom;given-names:A.A.</infon><infon key="name_3">surname:Kumar;given-names:B.</infon><infon key="pub-id_doi">10.1007/s13337-021-00702-6</infon><infon key="pub-id_pmid">34099981</infon><infon key="section_type">REF</infon><infon key="source">Virusdisease</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2021</infon><offset>23557</offset><text>Assessment of nitric oxide (NO) potential to mitigate COVID-19 severity</text></passage><passage><infon key="fpage">33</infon><infon key="lpage">38</infon><infon key="name_0">surname:Isidori;given-names:A.M.</infon><infon key="pub-id_doi">10.1111/andr.12837</infon><infon key="pub-id_pmid">32526061</infon><infon key="section_type">REF</infon><infon key="source">Andrology</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2021</infon><offset>23629</offset><text>Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project</text></passage><passage><infon key="comment">discussion</infon><infon key="fpage">2796S</infon><infon key="issue">2791S-2795S</infon><infon key="lpage">2797S</infon><infon key="name_0">surname:Brosnan;given-names:M.E.</infon><infon key="name_1">surname:Brosnan;given-names:J.T.</infon><infon key="pub-id_doi">10.1093/jn/134.10.2791S</infon><infon key="section_type">REF</infon><infon key="source">J Nutr</infon><infon key="type">ref</infon><infon key="volume">134</infon><infon key="year">2004</infon><offset>23706</offset><text>Renal arginine metabolism</text></passage><passage><infon key="fpage">167</infon><infon key="lpage">187</infon><infon key="name_0">surname:Wu;given-names:G.</infon><infon key="name_1">surname:Meininger;given-names:C.J.</infon><infon key="name_2">surname:McNeal;given-names:C.J.</infon><infon key="name_3">surname:Bazer;given-names:F.W.</infon><infon key="name_4">surname:Rhoads;given-names:J.M.</infon><infon key="pub-id_doi">10.1007/978-3-030-74180-8_10</infon><infon key="pub-id_pmid">34251644</infon><infon key="section_type">REF</infon><infon key="source">Adv Exp Med Biol</infon><infon key="type">ref</infon><infon key="volume">1332</infon><infon key="year">2021</infon><offset>23732</offset><text>Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans</text></passage><passage><infon key="fpage">532</infon><infon key="name_0">surname:Rath;given-names:M.</infon><infon key="name_1">surname:Muller;given-names:I.</infon><infon key="name_2">surname:Kropf;given-names:P.</infon><infon key="name_3">surname:Closs;given-names:E.I.</infon><infon key="name_4">surname:Munder;given-names:M.</infon><infon key="pub-id_doi">10.3389/fimmu.2014.00532</infon><infon key="pub-id_pmid">25386178</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2014</infon><offset>23798</offset><text>Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages</text></passage><passage><infon key="name_0">surname:Gambardella;given-names:J.</infon><infon key="pub-id_doi">10.3390/biomedicines8080277</infon><infon key="section_type">REF</infon><infon key="source">Biomedicines</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2020</infon><offset>23895</offset><text>Arginine and Endothelial Function</text></passage><passage><infon key="fpage">521</infon><infon key="lpage">531</infon><infon key="name_0">surname:Andrew;given-names:P.J.</infon><infon key="name_1">surname:Mayer;given-names:B.</infon><infon key="pub-id_doi">10.1016/s0008-6363(99)00115-7</infon><infon key="pub-id_pmid">10690324</infon><infon key="section_type">REF</infon><infon key="source">Cardiovasc Res</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">1999</infon><offset>23929</offset><text>Enzymatic function of nitric oxide synthases</text></passage><passage><infon key="fpage">258</infon><infon key="lpage">266</infon><infon key="name_0">surname:Jorens;given-names:P.G.</infon><infon key="name_1">surname:Vermeire;given-names:P.A.</infon><infon key="name_2">surname:Herman;given-names:A.G.</infon><infon key="pub-id_pmid">7680323</infon><infon key="section_type">REF</infon><infon key="source">Eur Respir J</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1993</infon><offset>23974</offset><text>L-arginine-dependent nitric oxide synthase: a new metabolic pathway in the lung and airways</text></passage><passage><infon key="fpage">4</infon><infon key="lpage">18</infon><infon key="name_0">surname:Tousoulis;given-names:D.</infon><infon key="name_1">surname:Kampoli;given-names:A.M.</infon><infon key="name_2">surname:Tentolouris;given-names:C.</infon><infon key="name_3">surname:Papageorgiou;given-names:N.</infon><infon key="name_4">surname:Stefanadis;given-names:C.</infon><infon key="pub-id_doi">10.2174/157016112798829760</infon><infon key="pub-id_pmid">22112350</infon><infon key="section_type">REF</infon><infon key="source">Curr Vasc Pharmacol</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2012</infon><offset>24066</offset><text>The role of nitric oxide on endothelial function</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">17</infon><infon key="name_0">surname:Dormanns;given-names:K.</infon><infon key="name_1">surname:Brown;given-names:R.G.</infon><infon key="name_2">surname:David;given-names:T.</infon><infon key="pub-id_doi">10.1016/j.jtbi.2016.01.009</infon><infon key="pub-id_pmid">26796228</infon><infon key="section_type">REF</infon><infon key="source">J Theor Biol</infon><infon key="type">ref</infon><infon key="volume">394</infon><infon key="year">2016</infon><offset>24115</offset><text>The role of nitric oxide in neurovascular coupling</text></passage><passage><infon key="fpage">515</infon><infon key="lpage">520</infon><infon key="name_0">surname:Ströhle;given-names:A.</infon><infon key="name_1">surname:von Bibra;given-names:H.</infon><infon key="name_2">surname:Hahn;given-names:A.</infon><infon key="pub-id_pmid">29979511</infon><infon key="section_type">REF</infon><infon key="source">Med Monatsschr Pharm</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">2016</infon><offset>24166</offset><text>[L-Arginine and vascular health]</text></passage><passage><infon key="fpage">641</infon><infon key="lpage">654</infon><infon key="name_0">surname:Bronte;given-names:V.</infon><infon key="name_1">surname:Zanovello;given-names:P.</infon><infon key="pub-id_doi">10.1038/nri1668</infon><infon key="pub-id_pmid">16056256</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Immunol</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2005</infon><offset>24199</offset><text>Regulation of immune responses by L-arginine metabolism</text></passage><passage><infon key="fpage">1426</infon><infon key="lpage">1463</infon><infon key="name_0">surname:Wijnands;given-names:K.A.</infon><infon key="name_1">surname:Castermans;given-names:T.M.</infon><infon key="name_2">surname:Hommen;given-names:M.P.</infon><infon key="name_3">surname:Meesters;given-names:D.M.</infon><infon key="name_4">surname:Poeze;given-names:M.</infon><infon key="pub-id_doi">10.3390/nu7031426</infon><infon key="pub-id_pmid">25699985</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2015</infon><offset>24255</offset><text>Arginine and citrulline and the immune response in sepsis</text></passage><passage><infon key="name_0">surname:Morelli;given-names:M.B.</infon><infon key="name_1">surname:Gambardella;given-names:J.</infon><infon key="name_2">surname:Castellanos;given-names:V.</infon><infon key="name_3">surname:Trimarco;given-names:V.</infon><infon key="name_4">surname:Santulli;given-names:G.</infon><infon key="pub-id_doi">10.3390/antiox9121227</infon><infon key="section_type">REF</infon><infon key="source">Antioxidants (Basel)</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2020</infon><offset>24313</offset><text>Vitamin C and Cardiovascular Disease: An Update</text></passage><passage><infon key="name_0">surname:Soto;given-names:M.E.</infon><infon key="name_1">surname:Guarner-Lans;given-names:V.</infon><infon key="name_2">surname:Soria-Castro;given-names:E.</infon><infon key="name_3">surname:Manzano Pech;given-names:L.</infon><infon key="name_4">surname:Perez-Torres;given-names:I.</infon><infon key="section_type">REF</infon><infon key="source">Medicina (Kaunas) 56, doi:10.3390/medicina56080386</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>24361</offset><text>Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application</text></passage><passage><infon key="fpage">1039</infon><infon key="lpage">1048</infon><infon key="name_0">surname:Montel-Hagen;given-names:A.</infon><infon key="pub-id_doi">10.1016/j.cell.2008.01.042</infon><infon key="pub-id_pmid">18358815</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">132</infon><infon key="year">2008</infon><offset>24472</offset><text>Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C</text></passage><passage><infon key="fpage">13816</infon><infon key="lpage">13819</infon><infon key="name_0">surname:Wang;given-names:Y.</infon><infon key="pub-id_doi">10.1073/pnas.94.25.13816</infon><infon key="pub-id_pmid">9391110</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci U S A</infon><infon key="type">ref</infon><infon key="volume">94</infon><infon key="year">1997</infon><offset>24569</offset><text>Ascorbate recycling in human neutrophils: induction by bacteria</text></passage><passage><infon key="name_0">surname:Bauer;given-names:S.R.</infon><infon key="name_1">surname:Kapoor;given-names:A.</infon><infon key="name_2">surname:Rath;given-names:M.</infon><infon key="name_3">surname:Thomas;given-names:S.A.</infon><infon key="pub-id_doi">10.3949/ccjm.87a.ccc046</infon><infon key="section_type">REF</infon><infon key="source">Cleve Clin J Med</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>24633</offset><text>What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19?</text></passage><passage><infon key="fpage">1379</infon><infon key="lpage">1390</infon><infon key="name_0">surname:Chavarria;given-names:A.P.</infon><infon key="pub-id_doi">10.1016/j.csbj.2021.02.009</infon><infon key="pub-id_pmid">33680348</infon><infon key="section_type">REF</infon><infon key="source">Comput Struct Biotechnol J</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2021</infon><offset>24767</offset><text>Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19</text></passage><passage><infon key="name_0">surname:Carr;given-names:A.C.</infon><infon key="name_1">surname:Rowe;given-names:S.</infon><infon key="pub-id_doi">10.3390/nu12113286</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2020</infon><offset>24902</offset><text>The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19</text></passage><passage><infon key="fpage">676</infon><infon key="lpage">684</infon><infon key="name_0">surname:Yan;given-names:J.</infon><infon key="name_1">surname:Tie;given-names:G.</infon><infon key="name_2">surname:Messina;given-names:L.M.</infon><infon key="pub-id_doi">10.2119/molmed.2011.00103</infon><infon key="pub-id_pmid">22371305</infon><infon key="section_type">REF</infon><infon key="source">Mol Med</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2012</infon><offset>24977</offset><text>Tetrahydrobiopterin, L-arginine and vitamin C act synergistically to decrease oxidative stress, increase nitricoxide and improve blood flow after induction of hindlimbischemia in the rat</text></passage><passage><infon key="fpage">433</infon><infon key="lpage">437</infon><infon key="name_0">surname:Kuck;given-names:J.L.</infon><infon key="pub-id_doi">10.1016/j.bbrc.2017.11.058</infon><infon key="pub-id_pmid">29129689</infon><infon key="section_type">REF</infon><infon key="source">Biochem Biophys Res Commun</infon><infon key="type">ref</infon><infon key="volume">495</infon><infon key="year">2018</infon><offset>25164</offset><text>Ascorbic acid attenuates endothelial permeability triggered by cell-free hemoglobin</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">8</infon><infon key="name_0">surname:Lundblad;given-names:C.</infon><infon key="name_1">surname:Bentzer;given-names:P.</infon><infon key="pub-id_doi">10.1016/j.mvr.2007.03.001</infon><infon key="pub-id_pmid">17459424</infon><infon key="section_type">REF</infon><infon key="source">Microvasc Res</infon><infon key="type">ref</infon><infon key="volume">74</infon><infon key="year">2007</infon><offset>25248</offset><text>Effects of L-arginine on cerebral blood flow, microvascular permeability, number of perfused capillaries, and brain water content in the traumatized mouse brain</text></passage><passage><infon key="fpage">701</infon><infon key="lpage">705</infon><infon key="name_0">surname:May;given-names:J.M.</infon><infon key="name_1">surname:Qu;given-names:Z.C.</infon><infon key="pub-id_doi">10.1016/j.bbrc.2010.12.046</infon><infon key="pub-id_pmid">21156160</infon><infon key="section_type">REF</infon><infon key="source">Biochem Biophys Res Commun</infon><infon key="type">ref</infon><infon key="volume">404</infon><infon key="year">2011</infon><offset>25409</offset><text>Nitric oxide mediates tightening of the endothelial barrier by ascorbic acid</text></passage><passage><infon key="name_0">surname:Carr;given-names:A.C.</infon><infon key="name_1">surname:Maggini;given-names:S.</infon><infon key="pub-id_doi">10.3390/nu9111211</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2017</infon><offset>25486</offset><text>Vitamin C and Immune Function</text></passage><passage><infon key="name_0">surname:Wang;given-names:C.</infon><infon key="pub-id_doi">10.3389/fcimb.2022.861703</infon><infon key="section_type">REF</infon><infon key="source">Front Cell Infect Microbiol</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2022</infon><offset>25516</offset><text>Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation</text></passage><passage><infon key="name_0">surname:Martinez-Salazar;given-names:B.</infon><infon key="pub-id_doi">10.3389/fcell.2022.824851</infon><infon key="section_type">REF</infon><infon key="source">Front Cell Dev Biol</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2022</infon><offset>25612</offset><text>COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences</text></passage><passage><infon key="fpage">626</infon><infon key="lpage">631</infon><infon key="name_0">surname:Sudre;given-names:C.H.</infon><infon key="pub-id_doi">10.1038/s41591-021-01292-y</infon><infon key="pub-id_pmid">33692530</infon><infon key="section_type">REF</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2021</infon><offset>25685</offset><text>Attributes and predictors of long COVID</text></passage><passage><infon key="name_0">surname:Mone;given-names:P.</infon><infon key="pub-id_doi">10.1124/jpet.122.001149</infon><infon key="section_type">REF</infon><infon key="source">J Pharmacol Exp Ther</infon><infon key="type">ref</infon><infon key="year">2022</infon><offset>25725</offset><text>L-Arginine Enhances the Effects of Cardiac Rehabilitation on Physical Performance: New Insights for Managing Cardiovascular Patients During the COVID-19 Pandemic</text></passage><passage><infon key="name_0">surname:Bustin;given-names:S.A.</infon><infon key="name_1">surname:Nolan;given-names:T.</infon><infon key="pub-id_doi">10.3390/ijms21083004</infon><infon key="section_type">REF</infon><infon key="source">Int J Mol Sci</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2020</infon><offset>25887</offset><text>RT-qPCR Testing of SARS-CoV-2: A Primer</text></passage><passage><infon key="name_0">surname:Sardu;given-names:C.</infon><infon key="pub-id_doi">10.3390/jcm9051417</infon><infon key="section_type">REF</infon><infon key="source">J Clin Med</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2020</infon><offset>25927</offset><text>Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence</text></passage><passage><infon key="fpage">306</infon><infon key="name_0">surname:Gambardella;given-names:J.</infon><infon key="pub-id_doi">10.1186/s13054-021-03731-1</infon><infon key="pub-id_pmid">34433473</infon><infon key="section_type">REF</infon><infon key="source">Crit Care</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2021</infon><offset>26077</offset><text>Role of endothelial miR-24 in COVID-19 cerebrovascular events</text></passage><passage><infon key="name_0">surname:Ambrosino;given-names:P.</infon><infon key="pub-id_doi">10.3390/biomedicines10040812</infon><infon key="section_type">REF</infon><infon key="source">Biomedicines</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2022</infon><offset>26139</offset><text>Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target</text></passage><passage><infon key="name_0">surname:Gambardella;given-names:J.</infon><infon key="pub-id_doi">10.1124/jpet.122.001209</infon><infon key="section_type">REF</infon><infon key="source">J Pharmacol Exp Ther</infon><infon key="type">ref</infon><infon key="year">2022</infon><offset>26232</offset><text>Exosomal miR-145 and miR-885 regulate thrombosis in COVID-19</text></passage><passage><infon key="fpage">155</infon><infon key="lpage">156</infon><infon key="name_0">surname:Seitz;given-names:A.</infon><infon key="name_1">surname:Ong;given-names:P.</infon><infon key="pub-id_doi">10.1016/j.ijcard.2021.11.051</infon><infon key="pub-id_pmid">34838682</infon><infon key="section_type">REF</infon><infon key="source">Int J Cardiol</infon><infon key="type">ref</infon><infon key="volume">349</infon><infon key="year">2022</infon><offset>26293</offset><text>Endothelial dysfunction in COVID-19: A potential predictor of long-COVID</text></passage><passage><infon key="name_0">surname:Oikonomou;given-names:E.</infon><infon key="pub-id_doi">10.1016/j.vph.2022.106975</infon><infon key="section_type">REF</infon><infon key="source">Vascul Pharmacol</infon><infon key="type">ref</infon><infon key="volume">144</infon><infon key="year">2022</infon><offset>26366</offset><text>Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study</text></passage><passage><infon key="fpage">228</infon><infon key="lpage">235</infon><infon key="name_0">surname:Blann;given-names:A.D.</infon><infon key="pub-id_doi">10.1160/TH04-09-0578</infon><infon key="section_type">REF</infon><infon key="source">Biomarker of vascular disease. Thromb Haemost</infon><infon key="type">ref</infon><infon key="volume">93</infon><infon key="year">2005</infon><offset>26454</offset><text>Circulating endothelial cells</text></passage><passage><infon key="fpage">1789</infon><infon key="lpage">1793</infon><infon key="name_0">surname:Guervilly;given-names:C.</infon><infon key="pub-id_doi">10.1093/infdis/jiaa528</infon><infon key="pub-id_pmid">32812049</infon><infon key="section_type">REF</infon><infon key="source">J Infect Dis</infon><infon key="type">ref</infon><infon key="volume">222</infon><infon key="year">2020</infon><offset>26484</offset><text>Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19</text></passage><passage><infon key="name_0">surname:Chioh;given-names:F.W.</infon><infon key="pub-id_doi">10.7554/eLife.64909</infon><infon key="section_type">REF</infon><infon key="source">Elife</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2021</infon><offset>26568</offset><text>Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation</text></passage><passage><infon key="name_0">surname:Vollenberg;given-names:R.</infon><infon key="pub-id_doi">10.3390/v13112324</infon><infon key="section_type">REF</infon><infon key="source">Viruses</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2021</infon><offset>26678</offset><text>Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis</text></passage><passage><infon key="fpage">2546</infon><infon key="lpage">2553</infon><infon key="name_0">surname:Fogarty;given-names:H.</infon><infon key="pub-id_doi">10.1111/jth.15490</infon><infon key="pub-id_pmid">34375505</infon><infon key="section_type">REF</infon><infon key="source">J Thromb Haemost</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2021</infon><offset>26804</offset><text>Persistent endotheliopathy in the pathogenesis of long COVID syndrome</text></passage><passage><infon key="name_0">surname:Charfeddine;given-names:S.</infon><infon key="pub-id_doi">10.3389/fcvm.2021.745758</infon><infon key="section_type">REF</infon><infon key="source">Front Cardiovasc Med</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2021</infon><offset>26874</offset><text>Long COVID 19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights From TUN-EndCOV Study</text></passage><passage><infon key="fpage">2251</infon><infon key="lpage">2252</infon><infon key="name_0">surname:Datta;given-names:S.D.</infon><infon key="name_1">surname:Talwar;given-names:A.</infon><infon key="name_2">surname:Lee;given-names:J.T.</infon><infon key="pub-id_doi">10.1001/jama.2020.22717</infon><infon key="pub-id_pmid">33206133</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">324</infon><infon key="year">2020</infon><offset>26992</offset><text>A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications</text></passage><passage><infon key="name_0">surname:Taboada;given-names:M.</infon><infon key="name_1">surname:Caruezo;given-names:V.</infon><infon key="name_2">surname:Naveira;given-names:A.</infon><infon key="name_3">surname:Atanassoff;given-names:P.G.</infon><infon key="pub-id_doi">10.1016/j.jclinane.2020.109926</infon><infon key="section_type">REF</infon><infon key="source">J Clin Anesth</infon><infon key="type">ref</infon><infon key="volume">66</infon><infon key="year">2020</infon><offset>27144</offset><text>Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease</text></passage><passage><infon key="fpage">1441</infon><infon key="name_0">surname:Garcia;given-names:L.F.</infon><infon key="pub-id_doi">10.3389/fimmu.2020.01441</infon><infon key="pub-id_pmid">32612615</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2020</infon><offset>27217</offset><text>Immune Response, Inflammation, and the Clinical Spectrum of COVID-19</text></passage><passage><infon key="fpage">e594</infon><infon key="lpage">e602</infon><infon key="name_0">surname:Manson;given-names:J.J.</infon><infon key="pub-id_doi">10.1016/S2665-9913(20)30275-7</infon><infon key="pub-id_pmid">32864628</infon><infon key="section_type">REF</infon><infon key="source">Lancet Rheumatol</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2020</infon><offset>27286</offset><text>COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study</text></passage><passage><infon key="fpage">363</infon><infon key="lpage">374</infon><infon key="name_0">surname:Tay;given-names:M.Z.</infon><infon key="name_1">surname:Poh;given-names:C.M.</infon><infon key="name_2">surname:Renia;given-names:L.</infon><infon key="name_3">surname:MacAry;given-names:P.A.</infon><infon key="name_4">surname:Ng;given-names:L.F.P.</infon><infon key="pub-id_doi">10.1038/s41577-020-0311-8</infon><infon key="pub-id_pmid">32346093</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Immunol</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2020</infon><offset>27398</offset><text>The trinity of COVID-19: immunity, inflammation and intervention</text></passage><passage><infon key="name_0">surname:Budinger;given-names:G.R.S.</infon><infon key="name_1">surname:Misharin;given-names:A.V.</infon><infon key="name_2">surname:Ridge;given-names:K.M.</infon><infon key="name_3">surname:Singer;given-names:B.D.</infon><infon key="name_4">surname:Wunderink;given-names:R.G.</infon><infon key="pub-id_doi">10.1172/JCI149412</infon><infon key="section_type">REF</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="volume">131</infon><infon key="year">2021</infon><offset>27463</offset><text>Distinctive features of severe SARS-CoV-2 pneumonia</text></passage><passage><infon key="fpage">741</infon><infon key="lpage">745</infon><infon key="name_0">surname:Lavine;given-names:J.S.</infon><infon key="name_1">surname:Bjornstad;given-names:O.N.</infon><infon key="name_2">surname:Antia;given-names:R.</infon><infon key="pub-id_doi">10.1126/science.abe6522</infon><infon key="pub-id_pmid">33436525</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">371</infon><infon key="year">2021</infon><offset>27515</offset><text>Immunological characteristics govern the transition of COVID-19 to endemicity</text></passage><passage><infon key="fpage">228</infon><infon key="name_0">surname:Lucas;given-names:R.</infon><infon key="pub-id_doi">10.3389/fimmu.2013.00228</infon><infon key="pub-id_pmid">23966993</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2013</infon><offset>27593</offset><text>Arginase 1: an unexpected mediator of pulmonary capillary barrier dysfunction in models of acute lung injury</text></passage><passage><infon key="fpage">515</infon><infon key="lpage">525</infon><infon key="name_0">surname:Reizine;given-names:F.</infon><infon key="pub-id_doi">10.1007/s10875-020-00920-5</infon><infon key="pub-id_pmid">33387156</infon><infon key="section_type">REF</infon><infon key="source">J Clin Immunol</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2021</infon><offset>27702</offset><text>SARS-CoV-2-Induced ARDS Associates with MDSC Expansion, Lymphocyte Dysfunction, and Arginine Shortage</text></passage><passage><infon key="name_0">surname:Dean;given-names:M.J.</infon><infon key="pub-id_doi">10.1101/2021.03.26.21254441</infon><infon key="section_type">REF</infon><infon key="source">medRxiv</infon><infon key="type">ref</infon><infon key="year">2021</infon><offset>27804</offset><text>Transcriptome and Functions of Granulocytic Myeloid-Derived Suppressor Cells Determine their Association with Disease Severity of COVID-19</text></passage><passage><infon key="name_0">surname:Sacchi;given-names:A.</infon><infon key="pub-id_doi">10.3390/cells10082111</infon><infon key="section_type">REF</infon><infon key="source">Cells</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2021</infon><offset>27943</offset><text>Expansion of Myeloid Derived Suppressor Cells Contributes to Platelet Activation by L-Arginine Deprivation during SARS-CoV-2 Infection</text></passage><passage><infon key="name_0">surname:Gelzo;given-names:M.</infon><infon key="pub-id_doi">10.3390/v14030534</infon><infon key="section_type">REF</infon><infon key="source">Viruses</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2022</infon><offset>28078</offset><text>Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves</text></passage><passage><infon key="fpage">2121</infon><infon key="lpage">2127</infon><infon key="name_0">surname:Cinar;given-names:R.</infon><infon key="name_1">surname:Iyer;given-names:M.R.</infon><infon key="name_2">surname:Kunos;given-names:G.</infon><infon key="pub-id_doi">10.1111/bph.15461</infon><infon key="pub-id_pmid">33769552</infon><infon key="section_type">REF</infon><infon key="source">Br J Pharmacol</infon><infon key="type">ref</infon><infon key="volume">179</infon><infon key="year">2022</infon><offset>28183</offset><text>Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19</text></passage><passage><infon key="fpage">n1648</infon><infon key="name_0">surname:Crook;given-names:H.</infon><infon key="name_1">surname:Raza;given-names:S.</infon><infon key="name_2">surname:Nowell;given-names:J.</infon><infon key="name_3">surname:Young;given-names:M.</infon><infon key="name_4">surname:Edison;given-names:P.</infon><infon key="pub-id_doi">10.1136/bmj.n1648</infon><infon key="pub-id_pmid">34312178</infon><infon key="section_type">REF</infon><infon key="source">BMJ</infon><infon key="type">ref</infon><infon key="volume">374</infon><infon key="year">2021</infon><offset>28317</offset><text>Long covid-mechanisms, risk factors, and management</text></passage><passage><infon key="fpage">631</infon><infon key="lpage">641</infon><infon key="name_0">surname:Azizi;given-names:S.A.</infon><infon key="name_1">surname:Azizi;given-names:S.A.</infon><infon key="pub-id_doi">10.1007/s13365-020-00903-7</infon><infon key="pub-id_pmid">32876900</infon><infon key="section_type">REF</infon><infon key="source">J Neurovirol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2020</infon><offset>28369</offset><text>Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells</text></passage><passage><infon key="fpage">1473</infon><infon key="lpage">1487</infon><infon key="name_0">surname:Castanares-Zapatero;given-names:D.</infon><infon key="pub-id_doi">10.1080/07853890.2022.2076901</infon><infon key="pub-id_pmid">35594336</infon><infon key="section_type">REF</infon><infon key="source">Ann Med</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">2022</infon><offset>28505</offset><text>Pathophysiology and mechanism of long COVID: a comprehensive review</text></passage><passage><infon key="fpage">1745</infon><infon key="name_0">surname:Rutkai;given-names:I.</infon><infon key="pub-id_doi">10.1038/s41467-022-29440-z</infon><infon key="pub-id_pmid">35365631</infon><infon key="section_type">REF</infon><infon key="source">Nat Commun</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2022</infon><offset>28573</offset><text>Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates</text></passage><passage><infon key="name_0">surname:Prasannan;given-names:N.</infon><infon key="pub-id_doi">10.1182/bloodadvances.2021006944</infon><infon key="section_type">REF</infon><infon key="source">Blood Adv</infon><infon key="type">ref</infon><infon key="year">2022</infon><offset>28649</offset><text>Impaired exercise capacity in post-COVID syndrome: the role of VWF-ADAMTS13 axis</text></passage><passage><infon key="fpage">7</infon><infon key="name_0">surname:Suh;given-names:S.Y.</infon><infon key="pub-id_doi">10.1186/1475-2891-11-7</infon><infon key="pub-id_pmid">22264303</infon><infon key="section_type">REF</infon><infon key="source">Nutr J</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2012</infon><offset>28730</offset><text>Intravenous vitamin C administration reduces fatigue in office workers: a double-blind randomized controlled trial</text></passage><passage><infon key="fpage">139</infon><infon key="lpage">146</infon><infon key="name_0">surname:Stephenson;given-names:C.M.</infon><infon key="name_1">surname:Levin;given-names:R.D.</infon><infon key="name_2">surname:Spector;given-names:T.</infon><infon key="name_3">surname:Lis;given-names:C.G.</infon><infon key="pub-id_doi">10.1007/s00280-013-2179-9</infon><infon key="pub-id_pmid">23670640</infon><infon key="section_type">REF</infon><infon key="source">Cancer Chemother Pharmacol</infon><infon key="type">ref</infon><infon key="volume">72</infon><infon key="year">2013</infon><offset>28845</offset><text>Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer</text></passage><passage><infon key="fpage">4104</infon><infon key="lpage">4108</infon><infon key="name_0">surname:Ceriello;given-names:A.</infon><infon key="pub-id_doi">10.2337/dc13-0750</infon><infon key="pub-id_pmid">24130351</infon><infon key="section_type">REF</infon><infon key="source">Diabetes Care</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2013</infon><offset>28999</offset><text>Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes</text></passage><passage><infon key="fpage">103</infon><infon key="name_0">surname:Gillani;given-names:S.W.</infon><infon key="name_1">surname:Sulaiman;given-names:S.A.S.</infon><infon key="name_2">surname:Abdul;given-names:M.I.M.</infon><infon key="name_3">surname:Baig;given-names:M.R.</infon><infon key="pub-id_doi">10.1186/s12933-017-0584-9</infon><infon key="pub-id_pmid">28807030</infon><infon key="section_type">REF</infon><infon key="source">Cardiovasc Diabetol</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2017</infon><offset>29184</offset><text>Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>29371</offset><text>Supplementary material</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>29394</offset><text>Appendix B</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>29405</offset><text>List of physicians who participated in the LINCOLN study and their affiliations.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>29486</offset><text>Data availability</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>29504</offset><text>Data will be made available on request.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>29544</offset><text>Supplementary data associated with this article can be found in the online version at doi:10.1016/j.phrs.2022.106360.</text></passage></document></collection>
